Revance Therapeutics, Stock Price To Earnings To Growth
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
Revance Therapeutics, fundamentals help investors to digest information that contributes to Revance Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Revance Stock. The fundamental analysis module provides a way to measure Revance Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Revance Therapeutics, stock.
Revance |
Revance Therapeutics, Company Price To Earnings To Growth Analysis
Revance Therapeutics,'s PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Revance Therapeutics, Price To Earnings To Growth | (0.64) X |
Most of Revance Therapeutics,'s fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Revance Therapeutics, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Revance Therapeutics, has a Price To Earnings To Growth of -0.64 times. This is 190.14% lower than that of the Pharmaceuticals sector and 120.38% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 113.09% higher than that of the company.
Revance Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revance Therapeutics,'s direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Revance Therapeutics, could also be used in its relative valuation, which is a method of valuing Revance Therapeutics, by comparing valuation metrics of similar companies.Revance Therapeutics, is currently under evaluation in price to earnings to growth category among its peers.
Revance Fundamentals
| Return On Equity | -20.97 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (0.72) % | |||
| Operating Margin | (0.54) % | |||
| Current Valuation | 680.39 M | |||
| Shares Outstanding | 104.39 M | |||
| Shares Owned By Insiders | 8.55 % | |||
| Shares Owned By Institutions | 87.45 % | |||
| Number Of Shares Shorted | 4.51 M | |||
| Price To Earning | (7.60) X | |||
| Price To Book | 12.30 X | |||
| Price To Sales | 1.48 X | |||
| Revenue | 234.04 M | |||
| Gross Profit | 103.69 M | |||
| EBITDA | (290.64 M) | |||
| Net Income | (323.99 M) | |||
| Cash And Equivalents | 233.82 M | |||
| Cash Per Share | 3.20 X | |||
| Total Debt | 478.43 M | |||
| Debt To Equity | 2.94 % | |||
| Current Ratio | 3.38 X | |||
| Book Value Per Share | (1.55) X | |||
| Cash Flow From Operations | (216.57 M) | |||
| Short Ratio | 1.70 X | |||
| Earnings Per Share | (3.34) X | |||
| Price To Earnings To Growth | (0.64) X | |||
| Target Price | 9.47 | |||
| Number Of Employees | 597 | |||
| Beta | 0.95 | |||
| Market Capitalization | 381.02 M | |||
| Total Asset | 478.45 M | |||
| Retained Earnings | (2.08 B) | |||
| Working Capital | 249.64 M | |||
| Current Asset | 208.68 M | |||
| Current Liabilities | 17.52 M | |||
| Net Asset | 478.45 M |
About Revance Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Revance Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revance Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revance Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |